Investor Relations

Steven Block steps down; Scott Heinzelman appointed as new President to drive Ambu’s strong growth trajectory in North America. 

Effective 25 August 2025, Ambu announces the appointment of Scott Heinzelman as President of the North America commercial region. He succeeds Steven Block, who has decided to step down after 12 years of dedicated leadership to begin a new chapter in semi-retirement. 

Scott Heinzelman is a seasoned commercial executive with extensive experience in driving strong growth and organizational transformation. He is a US native with more than two decades of experience from the medtech industry, having held senior leadership roles at global healthcare companies, such as Abbott, Orthofix, and Covidien (now Medtronic). Most recently, he served as Divisional Vice President of Abbott Vascular’s US Commercial business, where he led a $1 billion organization, built a specialized sales force, launched breakthrough therapies, and delivered growth that outpaced the market. Prior to that, he held roles as Divisional Vice President of Sales & Marketing and Global Head of Commercial Excellence, with responsibility for commercial strategy, P&L performance, and commercial infrastructure. 

Throughout his career, Scott has demonstrated a strong ability to shape commercial strategy, drive sustainable and profitable growth, and lead high-performing sales organizations with a sharp focus on execution across complex business environments. His leadership is characterized by strategic clarity, customer focus, and a collaborative mindset – qualities that have consistently delivered results and earned the trust of customers, colleagues, and partners alike. 

“I am very excited to welcome Scott Heinzelman as our new President for Ambu North America. Scott brings a wealth of commercial experience and a proven ability to define and deliver a customer-focused high-growth agenda from leading medtech companies. His strong leadership skills, combined with his strategic and analytical capabilities, makes him a natural choice to lead our continued expansion and to strengthen our leadership position in the North American market.  

Also, I would like to thank Steven for leading our Ambu North America team over the past 12 years. He has played an instrumental role in driving a successful growth agenda and demonstrating strong leadership. I wish him all the best in his next life chapter.” 

BRITT MEELBY JENSEN 
Chief Executive Officer 

Leading the next phase of growth in North America 
Over the past decade, Ambu North America has achieved strong growth and is today a leading company in the US endoscopy market as well as a prominent player in the US medtech industry. The organization has an extensive presence in hospitals nationwide and contributes to improving care for millions of patients every year. Steven Block has played a central role in elevating Ambu’s North American business to this impactful position. 

With a strong foundation established and Scott Heinzelman appointed as President, Ambu is well-positioned to accelerate its growth ambitions in the North American market. He will join Ambu’s Executive Leadership Team as he takes on the responsibility for leading the next phase of growth and leadership in North America. 

“I'm honored to join this incredible organization at such an important time. Ambu has a history of customer-centric innovation and a strong culture; this is a winning formula for delivering strong results. It is a privilege to lead the North America organization into this next stage of high growth and profitability. Our focus is clear: deliver solutions that make a real difference in healthcare and patients’ lives. We’re not just aiming to grow – we’re aiming to lead.”  

SCOTT HEINZELMAN 
New President, Ambu North America 

Read and download the full press release here

In the third quarter of the 2024/25 financial year, Ambu delivered 12.0% organic revenue growth and an 11.3% EBIT margin before special items. This was driven by continued growth in Endoscopy Solutions, which grew 15.9%, and solid performance in Anesthesia & Patient Monitoring, which grew 6.4%. This brings the organic growth for the first nine months to 14.3% and the EBIT margin to 13.9%.  

The financial guidance for organic revenue growth for 2024/25 is updated to reflect the continued solid growth and is now expected to be 12-14% (previously 11-14%).  

“I am pleased with the continued solid growth momentum in our third quarter. With 15.9% growth in Endoscopy Solutions and portfolio expansions in pulmonology and urology, we are deepening our presence in high-growth markets. On the back of solid revenue performance in Endoscopy Solutions and strong growth in Anesthesia & Patient Monitoring, we are raising the lower end of our organic revenue guidance to 12-14% for the full year. We maintain our EBIT margin guidance, supported by solid organic growth and operational leverage, even as we navigate FX and tariff-related dynamics. 

I want to thank our teams for their dedication and execution, which makes this continued progress possible. We look forward to welcoming institutional investors, analysts, and financial media to attend our Capital Markets Day on 1 October 2025, where we will share insights on strategy and market opportunities.”  

BRITT MEELBY JENSEN
Chief Executive Officer 

Q3 HIGHLIGHTS 

Business highlights:

• Advancing pulmonology market leadership position with the expansion of Ambu® SureSight™ Connect video laryngoscopy solution for pediatric patients. 
• Strengthened urology offering with FDA clearance for Ambu® aScope™ 5 Cysto HD cysto-nephroscope for PCNL procedures.  
• Continued sustainability leadership with launch of first-of-its-kind endoscope tack-back and recycling program, the Ambu® Recircle Program, in key markets. 
• Scott Heinzelman appointed new President for North America and member of Ambu’s Executive Leadership Team, as of 25 August. 

Financial highlights: 

• Revenue increased organically by 12.0% (15.0%) to DKK 1,507m (DKK 1,383m), with reported growth of 9.0% (15.7%). Organic growth for the first nine months was 14.3% (14.9%), with reported growth of 14.2% (12.9%). 
• Endoscopy Solutions increased organically by 15.9% (18.0%). The Pulmonology business group posted 11.2% (9.9%) organic growth, positively impacted by continued aScope™ 5 Broncho adoption, as well as the newly launched video laryngoscopy solution. The Urology, ENT, & GI business group posted 20.8% (27.6%) organic growth, mainly driven by the aScope™ 4 portfolio, with sustained strong growth momentum for aScope™ 5 Uretero. 
• Anesthesia & Patient Monitoring increased organically by 6.4% (10.9%) and by 11.1% (6.4%) for the first nine months, driven by both volume and price increases.  
• EBIT before special items (b.s.i.) was DKK 170m (DKK 178m), with an EBIT margin b.s.i. of 11.3% (12.9%). EBIT b.s.i. for the first nine months ended at DKK 637m (DKK 498m), with an EBIT margin b.s.i. of 13.9% (12.4%). EBIT margin for the quarter was negatively impacted by both FX headwind and tariff costs but positively impacted by continued operational leverage from solid organic growth.   
• Free cash flow (FCF) before acquisitions totaled DKK 128m (DKK 163m), leaving FCF for the first nine months to DKK 277m. This was impacted by continued higher net working capital to mitigate the global geopolitical uncertainties and support growth, and profitability was impacted by both FX headwind and tariff costs. As a result, FCF assumptions for FY 2024/25 are now DKK ~400m (previously DKK +500m).  
• Raise of lower end of organic revenue guidance to 12-14% (previously 11-14%), driven by continued procedure growth and conversion towards single-use solutions. EBIT margin b.s.i. guidance is maintained, with investments continuing as planned to support long-term growth, despite FX headwind and increased tariff costs.
  ​2024/25 financial guidance: 
  • Organic revenue growth: 12-14% (previously 11-14%) 
  • EBIT margin b.s.i.: 13-15% 

Q3 2024/25 conference call 
A conference call is broadcast live today, 22 August 2025 at 11:00 (CEST),  
via ambu.com/webcastQ32025. To ask questions during the Q&A session, please register prior to the call via ambu.com/conferencecallQ32025register. Upon registration, you will receive an e-mail with information to access the call.  

The presentation can be downloaded at Ambu.com/presentations.

 

Read and download the full Q3 earning release here

Ambu invites institutional investors, analysts, and financial media to the company’s Capital Markets Day on Wednesday 1 October 2025.

Ambu is pleased to invite institutional investors, analysts, and financial media to attend our Capital Markets Day on 1 October 2025 from 10:00-16:30 CEST, at the headquarters of Ambu A/S, Baltorpbakken 13, 2750 Ballerup, Denmark. 

The purpose of the event is to share insights on strategy and market opportunities. Furthermore, it is an opportunity to meet with the broader executive leadership team, as well as key external speakers. Finally, there will be a product demonstration at the end of the event, offering participants the opportunity to experience Ambu’s solutions firsthand. 

All presentations and Q&As are held from 10:00-15:00 CEST. The presentations will be held in English, and they will be recorded. After the event, the recorded presentations and the presentation materials will be published on Ambu’s website.   

The product demonstration will run from 15:00-16:30 CEST and will be for in-person attendees only.

SIGN UP FOR IN-PERSON ATTENDANCE 
We encourage you to sign up for in-person attendance now by writing directly to Louise Alstrup, Executive Assistant.

Please register your in-person attendance no later than Friday 19 September 2025.  

Due to capacity constraints, please note that institutional investors, stock analysts, and financial media are given in-person attendance priority to the event. Private investors are encouraged to follow the event online.  

FOLLOW THE EVENT ONLINE  
Ambu’s Capital Markets Day 2025 will be broadcasted live, and a video streaming link will be added to the Investor Relations site on the company’s website prior to the event. 

Please note that online attendees will not be able to ask questions during the Q&A sessions. In addition, the product demonstration from 15:00-16:30 CEST will not be livestreamed during the event. Instead, it will take place for in-person attendees only. 

We look forward to seeing you at Ambu’s Capital Markets Day 2025.  

Download the full invitation here.